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Background
A heterozygous frameshift (fs) mutation causing a 12
amino acid extension to the C-terminus of atrial natriu-
retic peptide (ANP) was recently genetically linked to
patients with familial atrial fibrillation [1]. The frameshift
product (fsANP), but not wild type ANP (wtANP), was
elevated in the serum of affected patients, but the molec-
ular basis for the elevated peptide concentrations was not
determined. Here, we measured the ability of fsANP to
interact with natriuretic peptide receptors and to be prote-
olytically degraded.
Methods and results
We comprehensively analyzed the function of the
frameshift mutation by measuring its receptor interaction
properties and its susceptibility to proteolysis. FsANP and
wtANP bound and activated cognate cell surface receptors,
NPR-A and NPR-C, similarly while fsANP had a slightly
increased efficacy for human NPR-B. Proteolytic suscepti-
bility was addressed with novel bioassays that measure
the time required for human kidney membranes or puri-
fied neutral endopeptidase to abolish ANP-dependent
activation of human NPR-A. Using human kidney mem-
branes, we determined that the half-life of fsANP (4.5
min) was significantly longer than the half-life of wtANP
(2.6 min). Additional membrane proteolysis studies indi-
cated that wtANP and fsANP are preferentially degraded
by neutral endopeptidase and serine peptidases, respec-
tively.
Conclusion
These data indicate that the familial ANP frameshift muta-
tion associated with atrial fibrillation has only minor
effects on natriuretic peptide receptor interactions but
markedly decreases peptide proteolysis.
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